Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan.

ABSTRACT:

Background

The antibody-drug conjugate sacituzumab govitecan is approved for metastatic triple-negative breast cancer and has shown promising results in various other types of cancer. Its costs may limit patient access to this novel effective treatment modality.

Objective

The purpose of this study was to develop an evidence-based rational dosing regimen that results in targeted drug exposure within the therapeutic range while minimizing financial toxicity, to improve treatment access.

Patients and methods

Exposure equivalent dosing strategies were developed based on pharmacokinetic modeling and simulation by using the published pharmacokinetic model developed by the license holder. The alternative dose was based on the principle of using complete vials to prevent spil

SUBMITTER: Moes DJAR 

PROVIDER: S-EPMC11393053 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature